Contineum Therapeutics Inc Dossier - Source-backed chat

Contineum Therapeutics Inc

CTNMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.83

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $12.99Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $488.7M

Enterprise Value $474M

Shares Outstanding 39.2M diluted

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Contineum Therapeutics is a clinical-stage biopharmaceutical company pioneering oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. While the company suffered a setback in November 2025 when its J&J-partnered candidate, PIPE-307, failed to meet endpoints in a Phase 2 trial for relapsing-remitting multiple sclerosis (RRMS), the investment thesis remains highly attractive. The primary value driver is PIPE-791, a wholly-owned LPA1 receptor antagonist currently in a global Phase 2 trial (PROPEL-IPF) for idiopathic pulmonary fibrosis (IPF), with top-line results expected in the second half of 2026. Backed by a robust cash position of $246.3M (funding operations through 2027) and an upcoming Phase 2 readout for PIPE-307 in depression in mid-2026, Contineum offers a highly asymmetric risk-reward profile at its current valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.00

Mean target$22.33

High · most bullish analyst$28.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0015%

PIPE-791 fails to meet its primary safety or exploratory efficacy endpoints in the PROPEL-IPF trial, or exhibits unexpected toxicity. Additionally, PIPE-307 fails its Phase 2 depression trial, leading J&J to terminate the collaboration. With its lead programs compromised, the company is forced to rely on early-stage preclinical assets, leading to a severe valuation write-down.

Base CaseCentral scenario

$22.3360%

Matches the consensus mean

PIPE-791 shows positive, clinically meaningful trends in the PROPEL-IPF Phase 2 trial, supporting advancement into Phase 3. PIPE-307's depression trial yields mixed but supportive data, keeping J&J engaged in development. The company's cash position remains highly disciplined, preserving a runway into late 2027 without immediate dilutive financing.

Bull CaseUpside scenario

$28.0025%

PIPE-791 demonstrates superior efficacy and safety in the PROPEL-IPF Phase 2 trial in H2 2026, validating LPA1R as a blockbuster mechanism in a high-unmet-need market. Concurrently, PIPE-307 reads out positive Phase 2 data in Major Depressive Disorder (MDD) in mid-2026, prompting Johnson & Johnson to aggressively fund and advance the program. The company secures non-dilutive licensing revenue, extending its cash runway well beyond 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Wholly-owned lead asset (PIPE-791) targeting a clinically validated pathway (LPA1R) in Idiopathic Pulmonary Fibrosis (IPF), a high-value market with limited treatment options.
Strong balance sheet with $246.3M in cash and equivalents as of early 2026, providing a clear runway through 2027 and minimizing near-term dilution risk.
Ongoing high-profile collaboration with Johnson & Johnson (Janssen) for PIPE-307, providing validation and potential milestone/royalty streams.
Encouraging clinical data from PIPE-791 in chronic pain, demonstrating safety, tolerability, and positive numerical trends over placebo.

Key Investment Risks

High clinical development risk, as highlighted by the Phase 2 failure of PIPE-307 in RRMS in November 2025.
Pre-revenue status with ongoing high R&D expenses, making the company entirely dependent on capital markets or partner milestones for long-term survival.
Intense competition in the IPF and depression spaces from both established pharmaceutical companies and emerging biotechs.
Reliance on third-party partners (J&J/Janssen) who hold sole discretion over the future development and commercialization of PIPE-307.

Thesis Invalidation Triggers

Failure of PIPE-791 to meet primary endpoints in the PROPEL-IPF Phase 2 trial.
Termination of the PIPE-307 collaboration agreement by Johnson & Johnson following the Phase 2 depression readout.
Unexpected severe adverse events (SAEs) or safety signals in ongoing clinical trials for PIPE-791.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.